MediWound (MDWD) Company presentation summary

Market opportunity and technology platform

• Multibillion-dollar commercial potential with validated enzymatic technology for non-surgical tissue repair.

• Strategic global collaborations with leading healthcare and wound care companies.

• Proprietary, high-barrier manufacturing process using proteolytic enzymes from pineapple stem for rapid, selective tissue removal.

• New sterile manufacturing facility expands capacity sixfold, with regulatory approvals expected in 2026.

Product portfolio and pipeline

• NexoBrid® is a disruptive, non-surgical therapy for burn eschar removal, approved in 40+ countries and profitable with $17M revenue in 2025.

• EscharEx® is an investigational next-generation enzymatic therapy targeting chronic wounds, with a $2.5B+ U.S. market and de-risked Phase 3 program.

• Pipeline includes indications for venous leg ulcers (VLU), diabetic foot ulcers (DFU), and pressure ulcers, with multiple ongoing and planned trials.

• Extensive government and industry collaborations, including BARDA and DoD funding for NexoBrid.

Clinical efficacy and competitive positioning

• NexoBrid® demonstrated superior eschar removal, reduced need for surgery, and less blood loss compared to standard of care in Phase 3 trials.

• EscharEx® showed robust efficacy in Phase 2 trials, achieving faster and more complete debridement than placebo and traditional treatments.

• Head-to-head data indicate EscharEx® outperforms SANTYL in time to wound bed preparation, wound closure, and patient-reported pain.

• Both products are safe, well-tolerated, and align with current reimbursement and treatment workflows.